SAN DIEGO, California, USA, November 19, 2026
Acadia Pharmaceuticals Inc. has presented additional Phase 2 clinical data for remlifanserin, an investigational drug being developed to treat hallucinations and delusions associated with Alzheimer’s disease psychosis (ADP). The new analyses from the Phase 2 RADIANT clinical trial were presented at the 2026 Clinical Trials on Alzheimer’s Disease (CTAD) conference in Boston, highlighting consistent efficacy signals with once-daily 60 mg remlifanserin across multiple measures of psychosis and treatment timepoints.
Remlifanserin Demonstrates Efficacy Signals Across Psychosis Measures
The new findings build on previously announced topline results from the RADIANT trial, in which the 60 mg once-daily dose narrowly missed the primary endpoint, showing a −2.2-point improvement versus placebo on the SAPS-H+D Total Score at Week 6 (p=0.0603). However, the treatment achieved nominal statistical significance on the key secondary endpoint, CGI-S-ADP (p=0.0077). The 30 mg dose demonstrated minimal efficacy compared with placebo, supporting a potential dose-response relationship. Additional analyses showed that 60 mg remlifanserin was favored over placebo on the CGI-I-ADP scale at Weeks 2, 4 and 6, with nominal p-values of 0.0232, 0.0082 and 0.0208, respectively. At Week 6, 44.0% of patients receiving 60 mg were rated improved or very much improved, compared with 31.8% of patients receiving placebo, indicating a treatment response signal across multiple assessment periods.
New Analysis Highlights Treatment Response and Symptom Severity
Further data presented at CTAD showed that remlifanserin 60 mg separated from placebo on the Neuropsychiatric Inventory (NPI/NPI-NH) psychosis score at Week 4 (p=0.0084) and Week 6. At Week 6, the least-squares mean change was −7.3 for the 60 mg group versus −5.9 for placebo, with a nominal p-value of 0.0385 and an effect size of 0.29. The treatment also demonstrated separation from placebo on the CGI-S-ADP measure at Week 4 (p=0.0107) and Week 6. Additionally, the estimated treatment effect on the SAPS-H+D Total Score increased across progressively higher baseline psychosis severity thresholds. These findings provide further insights into how initial symptom severity may influence treatment response. Acadia stated that the additional analyses reinforce its confidence in the drug’s activity as development continues, although the Phase 2 primary endpoint was not met and the findings remain part of ongoing clinical evaluation.
Safety Findings and Continued Phase 3 Development
At the 60 mg dose, remlifanserin’s safety and tolerability profile remained consistent with previously reported results. Treatment-emergent adverse events occurred in 36.8% of patients compared with 41.7% for placebo, while drug-related adverse events were reported in 5.6% versus 7.8%. Serious adverse events occurred in 1.6% of patients receiving remlifanserin and 2.6% in the placebo group, while discontinuations due to adverse events were 2.4% and 2.6%, respectively. No deaths were reported in either remlifanserin arm. The study also found no negative impact on motor symptoms or cognition compared with placebo, and no patient assessed had a QTcF above 480 milliseconds or an increase exceeding 60 milliseconds. Based on these Phase 2 findings, Acadia continues advancing the Phase 3 portion of the RADIANT program to evaluate remlifanserin for Alzheimer’s disease psychosis. The drug is also being investigated in a separate Phase 2 study for Lewy body dementia psychosis, extending its development into another neurodegenerative disease-related psychosis indication.
Source: Acadia Pharmaceuticals press release



